Resectable stage I to III non-small-cell lung cancer: lines of therapy
5 standard-of-care settings across 2 lines and 3 biomarker subgroups. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.
Screening, prevention and diagnosis
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| All comers | Staging and surveillance | PET-CT and mediastinal sampling before surgery; CT every six months for two years then yearly; circulating tumour DNA surveillance in trials. | NCCN Guidelines: Non-Small Cell Lung Cancer | 92 |
Other settings
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| All comers | Stage IA, peripheral, 2 cm or less | Segmentectomy or lobectomy by video-assisted or robotic thoracoscopy with node dissection (CALGB 140503, JCOG0802); no systemic therapy; stereotactic radiotherapy if not fit for surgery. | NCCN Guidelines: Non-Small Cell Lung Cancer | 83 | |
| ALK | Resected ALK-positive stage IB to IIIA | Two years of adjuvant alectinib in place of chemotherapy (ALINA). | NCCN Guidelines: Non-Small Cell Lung Cancer | 86 | |
| EGFR | Stage IB to IIIA without EGFR or ALK alteration | Neoadjuvant nivolumab plus platinum chemotherapy for three cycles (CheckMate 816) or perioperative pembrolizumab (KEYNOTE-671), durvalumab (AEGEAN) or nivolumab (CheckMate 77T) with chemotherapy before and immunotherapy for a year after surgery; or surgery first then adjuvant cisplatin doublet and atezolizumab or pembrolizumab if PD-L1-positive (IMpower010). | CheckMate 816NivolumabKEYNOTE-671PembrolizumabA Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung CancerDurvalumabA Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung CancerStudy to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [AtezolizumabCisplatinCarboplatinPemetrexedNeoadjuvant / adjuvant / perioperativePathologic complete response (pCR)Major pathological response (MPR) | NCCN Guidelines: Non-Small Cell Lung Cancer | 98 |
| EGFR | Resected EGFR-mutated stage IB to IIIA | Adjuvant platinum chemotherapy where indicated, then three years of osimertinib (ADAURA). | NCCN Guidelines: Non-Small Cell Lung Cancer | 87 |
Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.